Categories: Health

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025

 | Source: Certara

RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Alyssa Horowitz
certara@pancomm.com

GlobeNews Wire

Recent Posts

NeuroDyne Drops: Sharp Mind, Enhanced Memory, and Lasting Focus As Nature Intended, Ingredients

NEURODYNE DROPS INTRODUCED AS A COGNITIVE WELLNESS SUPPLEMENT SUPPORTING HEALTHY MEMORY, FOCUS, AND MENTAL CLARITY…

3 hours ago

Optivell Officially Announced as a Vision Support Formula for Preventive Eye Wellness

New York City, NY, Jan. 17, 2026 (GLOBE NEWSWIRE) -- OPTIVELL INTRODUCED AS A NEW…

3 hours ago

Sugar Clean Drops: Top Blood Sugar Support Supplement for Metabolic Wellness and Energy Support

SUGAR CLEAN DROPS ANNOUNCED AS A NEW SUPPLEMENT SUPPORTING HEALTHY BLOOD SUGAR AND METABOLIC WELLNESS…

3 hours ago

DBV Technologies Announces 166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the…

14 hours ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 16:15 ET  | Source: Zenas BioPharma WALTHAM, Mass., Jan. 16, 2026 (GLOBE…

14 hours ago